Drug intelligence / Profile preview

DNP005

Development stage: Preclinical
Lead developer: KumhoHT
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

DNP005 is a preclinical-stage monoclonal antibody targeting CD40 (tumor necrosis factor receptor superfamily member 5) for the treatment of solid cancers. Originally developed by DiNonA and subsequently acquired by KumhoHT, DNP005 acts as a CD40 agonist to stimulate antigen-presenting cells, such as dendritic cells and B cells, thereby promoting T-cell activation and anti-tumor immune responses. In preclinical humanized NSG mouse xenograft models, DNP005 demonstrated significant efficacy, including complete tumor regression.

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on DNP005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNP005.